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Abstract
Background: Type 1 diabetes (T1DM) is frequently accompanied by dyslipidemia related with insulin-dependent
steps of the intravascular lipoprotein metabolism. T1DM dyslipidemia may predispose to precocious cardiovascular
disease and the lipid status in T1DM under intensive insulin treatment has not been sufficiently explored. The aim
was to investigate the plasma lipids and the metabolism of LDL and HDL in insulin-treated T1DM patients with
high glycemic levels.
Methods: Sixteen male patients with T1DM (26 ± 7 yrs) with glycated hemoglobin >7%, and 15 control subjects
(28 ± 6 yrs) were injected with a lipid nanoemulsion (LDE) resembling LDL and labeled with 14C-cholesteryl ester
and 3H-free-cholesterol for determination of fractional clearance rates (FCR, in h-1) and cholesterol esterification
kinetics. Transfer of labeled lipids from LDE to HDL was assayed in vitro.
Results: LDL-cholesterol (83 ± 15 vs 100 ± 29 mg/dl, p=0.08) tended to be lower in T1DM than in controls;
HDL-cholesterol and triglycerides were equal. LDE marker 14C-cholesteryl ester was removed faster from plasma in
T1DM patients than in controls (FCR=0.059 ± 0.022 vs 0.039 ± 0.022h-1, p=0.019), which may account for their lower
LDL-cholesterol levels. Cholesterol esterification kinetics and transfer of non-esterified and esterified cholesterol,
phospholipids and triglycerides from LDE to HDL were also equal.
Conclusion: T1DM patients under intensive insulin treatment but with poor glycemic control had lower
LDL-cholesterol with higher LDE plasma clearance, indicating that LDL plasma removal was even more efficient than in
controls. Furthermore, HDL-cholesterol and triglycerides, cholesterol esterification and transfer of lipids to HDL, an
important step in reverse cholesterol transport, were all normal. Coexistence of high glycemia levels with normal
intravascular lipid metabolism may be related to differences in exogenous insulin bioavailabity and different insulin
mechanisms of action on glucose and lipids. Those findings may have important implications for prevention of
macrovascular disease by intensive insulin treatment.
Keywords: Type 1 diabetes mellitus, Insulin treatment, Glycemia, Lipoprotein, Cholesterol metabolism, Lipids transfer,
Cardiovascular disease
Background
Patients with type 1 diabetes mellitus (T1DM) may present
disturbances of plasma lipids such as hypertriglyceridemia
and low HDL cholesterol and, less frequently, high LDL
cholesterol [1]. T1DM patients also show defects in the
regulation of the plasma lipid metabolism that are not
routinely evaluated, such as increase in the small dense
LDL subfraction [2], which is more atherogenic, and
dysfunctional HDL. In addition, alterations in the transfer
of lipids were found in those patients [3,4]. This process,
in which lipids are exchanged among lipoprotein classes,
depends on transfer proteins such as cholesteryl ester
transfer protein (CETP) and phospholipid transfer protein
(PLTP). Effective insulin treatment not only improves
glycemia but also the plasma lipid profile.
Lipoprotein metabolism in the intravascular compart-
ment can be probed by using artificial nanoemulsions
(LDE) with lipid structure that resembles LDL [5]. This
approach greatly facilitates the investigation of LDL
metabolism, since with a single preparation labeled
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with radioactivity or other means can be tested in several
patients. LDE is made without protein, but in contact with
plasma, the nanoemulsion particles gain exchangeable
apolipoproteins (apo), free or associated with the native
lipoproteins. Apo E acquired by LDE allows binding of the
LDE particles to LDL receptors and cell uptake via the
receptor-mediated endocytic pathway. LDE was validated
as a probe to detect changes in LDL metabolism in disease
states or under the action of drugs or dietary interventions
[6-8]. As an example, when injected into patients with
familial hypercholesterolemia, wherein LDL receptors are
defective, LDE was slowly removed from the circulation,
as it occurs when native LDL is injected [7]. On the other
hand, statin treatment accelerated the clearance of both
LDE and native LDL [9].
Recently, we described an in vitro assay in whole
plasma in which LDE was used as lipid donor to test the
simultaneous transfer of lipids to HDL [10]. Lipid transfer
is an essential step in the formation and metabolism of
HDL, and allows the action of the lipoprotein in cholesterol
esterification [11] and reverse cholesterol transport whereby
cholesterol is transported to the liver and excreted in bile.
Those are key processes for stabilization of the cholesterol
pool in the organism.
In T1DM, strict glycemic control achieved by intensive
insulin treatment can be beneficial for the prevention of
premature cardiovascular events, the major complication of
the disease [12]. In this approach, three or more daily
insulin injections are administered, aiming to achieve gly-
cemia as close as possible to normal levels. Insulin therapy
can achieve lower LDL and higher HDL cholesterol levels
[1] and may influence lipid transfers [4,13,14], composition
of lipoproteins [13] and rate of LDL production [15].
An aspect that has not been sufficiently addressed is
the status of lipid metabolism in T1DM patients under
intensive insulin treatment in whom elevated glycemia
persisted despite of the treatment. The aim of this study
was to investigate this issue since control of dyslipidemia
is key for the prevention of the diabetes-associated
macrovascular disease, the major cause of morbidity and
mortality of T1DM patients. The LDE plasma kinetic
approach was used to test the LDL metabolic pathway
and the transfer of lipids to HDL was evaluated by an
in vitro assay [10]. Male T1DM patients under intensive
insulin treatment but with high glycemic levels were
compared with non-diabetic controls of similar age.
Results
Lipids and apolipoproteins
The levels of LDL tend to be lower in T1DM patients
than in controls, although the difference did not attain
statistical significance. Comparing the two groups, non-
HDL cholesterol was lower, but HDL cholesterol and
triglyceride levels were equal (Table 1). The levels of apo
A1 and apo B were also equal in T1DM patients and
controls (Table 1).
LDE plasma kinetics
As shown in Figure 1A, it is apparent that the decay
curve of LDE 14C-cholesteryl esters obtained from the
T1DM patients is faster than that of the control subjects.
This is confirmed by the FCR of the LDE cholesteryl
esters, that was greater in T1DM patients than in controls
(0.059 ± 0.022 h-1 versus 0.039 ± 0.022 h-1, p=0.019)
(Table 2). Greater FCR in T1DM was due to greater k2.0,
since the other parameters of the compartmental analysis
of the curves were not different in the two groups. In
T1DM and controls, the FCR of LDE free cholesterol
was equal.
Cholesterol esterification
The esterification rates of LDE free cholesterol after the
injection into the T1DM patients were similar to that
observed in the control subjects in all points of the
decay curves (Table 3).
Lipid transfers to HDL
The transfer of the radioactive free and esterified
cholesterol, triglycerides and phospholipids from LDE
to HDL was not different in T1DM and control subjects
(Table 4).
Correlation analysis
In the correlation analysis performed between the data
of glycemia, glycated hemoglobin, estimated glucose
disposal rate and insulin dose per kilogram, on one hand,
and the data of FCR of free and esterified cholesterol,
cholesterol esterification rates and transfers to HDL of
Table 1 Serum biochemical parameters of the Type 1
Diabetes Mellitus (T1DM) and control groups
T1DM group
(n=15)
Control group
(n=16)
P value
Fasting blood glucose (mg/dl) 192 ± 96 81 ± 4 <0.001
Glycated hemoglobin (%) 8.8 ± 1.5 5.2 ± 0.4 <0.001
Insulin sensitivity* 6.7 ± 2.0 9.8 ± 0.7 <0.001
Cholesterol (mg/dl) 155 ± 26 174 ± 31 0.09
LDL 83 ± 15 100 ± 29 0.08
HDL 55 ± 14 56 ± 9 0.88
Non-HDL 99 ± 17 117 ± 29 0.05
Triglycerides 80 ± 39 81 ± 40 0.94
Apolipoproteins (mg/dl)
A1 127 ± 26 128 ± 17 0.91
B 67 ± 9 75 ± 23 0.26
Data are means ± SD. *Insulin sensitivity was estimated by glucose disposal
rate (EGDR), when EGDR = 24.31-12.22(WHR)-3.29(hypertension)-0.57(A1c).
WHR, waist-to-hip ratio.
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free and esterified cholesterol, triglycerides and phos-
pholipids, on the other hand, no significant correlations
were found.
Discussion
In this study, although their having high glycemic levels,
patients with T1DM under intensive insulin treatment
showed a trend for lower LDL cholesterol, as well as
faster removal of the LDE marker, 14C-cholesteryl ester
as compared with the control subjects.
LDL cholesterol concentration in the plasma is
determined by the balance between LDL production
rates and the LDL removal from the plasma, which is
largely dependent on the action of LDL receptors. In most
clinical situations, slow LDL removal, rather than increased
production rates, is the cause of hypercholesterolemia.
Nonetheless, in a recent study [16], we have shown that
the plasmatic removal of LDL, as monitored by LDE cho-
lesteryl ester FCR, was faster in athletes than in sedentary
subjects, although both groups had equal levels of LDL
cholesterol. Those results suggest that the increase in LDL
removal was compensated by increased LDL production.
LDL turnover in the plasma should be more often renewed
in athletes, and consequently the LDL peroxidation should
be diminished [16]. In contrast in patients with familial
hypercholesterolemia the plasma removal process of LDE
is delayed [9]. Delay in LDL clearance makes room for
increased lipoprotein peroxidation, uptake of oxidized LDL
by macrophage scavenger receptors and subsequent forma-
tion of foam cells [17]. In the present study, in T1DM
patients, the increased LDL removal, estimated by the LDE
kinetics, resulted indeed in a trend for diminution of LDL,
although not confirmed statistically. Non-HDL includes
not only LDL but also other VLDL catabolic products such
as intermediate density lipoprotein (IDL) and VLDL
remnants that are also removed by LDL receptors or by
LRP receptors [18]. Apo B concentration, that also marks
the non-HDL lipoproteins, also tended to be lower in our
Figure 1 Plasma decay curve of 14C-cholesteryl ester (A) and
3H-cholesterol (B) obtained from type 1 diabetes mellitus
(black square) and control (white square) groups. The doubly
labeled nanoemulsion was intravenously injected in a bolus, and
blood samples were drawn in pre-established intervals over 24 h for
measurement of the radioactivity in a scintillation solution. Data are
expressed as mean ± SD.
Table 2 Fractional clearance rates and kinetic parameters
of LDE radioactive lipid labels in the Type 1 Diabetes
Mellitus (T1DM) and control groups
T1DM group (n=15) Control group (n=16) P value
FCR 14C-CE 0.059 ± 0.022 0.039 ± 0.022 0.019
k1.0 14C-CE 0.352 ± 0.278 0.502 ± 0.567 0.97
k2.0 14C-CE 0.049 ± 0.024 0.026 ± 0.017 0.006
k1,2 14C-CE 1.939 ± 1.464 1.436 ± 1.425 0.35
FCR 3H-FC 0.025 ± 0.024 0.028 ± 0.024 0.78
k1,0 3H-FC 0.911 ± 0.731 0.866 ± 0.651 0.86
k2,0 3H-FC 0.016 ± 0.021 0.011 ± 0.010 0.98
k1,2 3H-FC 0.999 ± 0.972 0.677 ± 0.815 0.19
Data are means ± SD. FCR 14C-CE, fractional clearance rate of 14C-cholesteryl
ester. FCR 3H-CL, fractional clearance rate of 3H-free cholesterol. k1,0, constant
that represents removal of lipid to the extravascular space. k1,2, constant that
represents injected lipid which was converted into intravascular compartment.
k2,0, constant that represents materials of intravascular compartment which is
transferred to the extravascular space.
Table 3 Esterification ratio (3H-cholesterol/3H-cholesteryl
esters) in each point of the decay curves of labeled LDE
injected into the Type 1 Diabetes Mellitus (T1DM) and
control groups
T1DM group (n=15) Control group (n=16) P value
0.08 h 29.4 ± 11.5 27.4 ± 6.9 0.60
1 h 40.3 ± 15.1 35.0 ± 10.3 0.35
2 h 48.8 ± 14.1 45.6 ± 8.9 0.55
4 h 51.1 ± 12.3 49.5 ± 11 0.83
8 h 61.7 ± 11.8 55.9 ± 9.2 0.23
24 h 65.7 ± 9.6 63.1 ± 9.1 0.51
Data are expressed as mean ± SD.
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T1DM patients. Insulin can act on LDL receptors by
inducing receptor overexpression and increase in receptor
activity [19]. Therefore, the fast removal of LDE, shown in
the present study, was probably accounted for stimulation
of the LDL receptors consequent to peripheral hyperinsuli-
nemia in T1DM patients.
Insulin action on glycemia is exerted chiefly through
glucose cellular uptake mediated by GLUT4 [20] and
inhibition of glycogenolysis and gluconeogenesis [21].
The actions on lipoprotein metabolism are exerted
mainly through increase in lipolysis of triglyceride-rich
lipoproteins by stimulation of lipoprotein lipase [22],
and inhibition of lipolysis of fats stored in the tissues by
inhibition of hormone-sensitive lipase [23]. Apparently, the
subcutaneous insulin dose scheme that was insufficient to
optimize glycemia-related mechanisms of action had the
ability to optimize the LDL pathway.
Depending on the route of insulin administration, the
concentration of insulin in the peripheral circulation is
different from that of the portal circulation, which
conceivably has consequences on insulin availability and
action and differences between subcutaneous and intra-
peritonial routes were documented [24]. Administration
of excess exogenous insulin by subcutaneous route
increases the catabolic rates of apo B LDL [25], similarly
to our findings of increased LDE clearance in the T1DM
patients. Accelerated LDL clearance diminishes the
exposure of the lipoprotein to oxidation and other
pro-atherogenic effects [25].
LDE 3H-free cholesterol removal from the plasma was
similar in T1DM and controls, but the 14C-cholesteryl
ester label is more reliable as tracer of LDE decay in the
plasma than 3H-free cholesterol. In fact, 3H-free choles-
terol kinetics was designed to evaluate the cholesterol
esterification process in cases compared to controls. In
the plasma, LDE also gains apo A1, the LCAT co-factor so
that free cholesterol contained in LDE may suffer the
esterification reaction [11]. Another possibility is that free
cholesterol may partially shift from LDE to HDL, where it
can also be esterified.
Cholesterol esterification may be related with CAD: in
our previous study, we showed that in non-diabetic
CAD patients cholesterol esterification was higher [26].
Nonetheless, in this study, in all points of the LDE
decaying curves, cholesterol esterification did not statisti-
cally differ between T1DM and controls. Cholesterol
esterification and LCAT activity have been poorly explored
in T1DM. Chang et al. observed that the LCAT activity
was higher in T1DM with higher glycemic levels than in
those with lower glycemia [27], but comparisons with
non-diabetic controls were not reported. Our data showing
that LDE cholesterol esterification was equal in T1DM and
controls may be helpful for future targeting the status of
this reaction in T1DM with or without CAD.
T1DM patients treated with insulin also showed
normal levels of fasting triglyceridemia. In diabetes,
deficient function of insulin-dependent lipoprotein lipase
may lead not only to hypertriglyceridemia but also to
decreased HDL-cholesterol levels. This is the so-called
“see-saw effect” triglycerides-HDL cholesterol conse-
quent to increase in lipid exchanges between VLDL and
HDL. In respect to HDL, not only the HDL-cholesterol
and apo A1 levels were normal but also the metabolic
step of lipid transfers to HDL was normal in the T1DM
patients. Recently, it was shown that patients with
documented coronary artery disease had alterations in
lipid transfers to HDL such as decrease of free cholesterol
transfers to the lipoprotein [28].
In a previous study performed in women with polycystic
ovary syndrome [29], a correlation was found between
insulin resistance, measured by the HOMA-IR index and
that is associated with the syndrome, with the transfer of
triglycerides to HDL. On the other hand, the action of
both CETP and PLTP, that promote lipid transfer, was
found to be altered in T1DM patients, and in another
study CETP alterations were related with the presence of
macrovascular disease [30]. Thus, lack of differences in
lipid transfer in T1DM patients and controls may suggest
that intensive insulin treatment could have contributed to
the normal values in T1DM. Due to the importance of
lipid transfer for HDL remodeling and function, this result,
together with the finding of normal HDL-cholesterol and
apo A1 levels adds up for the protection of intensive
insulin treatment against macrovascular disease by
maintenance of normal plasma lipid metabolism pathways.
Native LDL is recognized by LDL receptors by means
of apo B, the only apo present in this lipoprotein. Recog-
nition of LDE by receptors through apo E, which has
greater affinity for the receptors results in removal of
LDE considerably faster than the native lipoprotein[8],
which facilitates the execution of the experimental
protocols and the comfort of the study subjects by
Table 4 Lipid transfer in vitro from LDE to HDL and HDL
particle size of the Type 1 Diabetes Mellitus (T1DM) and
control groups
T1DM group
(n=15)
Control group
(n=16)
P value
Lipid transfers (%)
Cholesteryl esters 2.7 ± 0,6 3.1 ± 0,8 0.09
Phospholipids 19.3 ± 3.7 20.7 ± 3.9 0.33
Tryglicerides 2.1 ± 0.8 2.3 ± 0.5 0.38
Free cholesterol 5.9 ± 1.7 6.0 ± 0.9 0.78
HDL particle size (nm) 10.4 ± 1.6 9.8 ± 1.2 0.20
Data are expressed as mean ± SD. The value indicated is the percentage of
the radioactivity of each lipid component in the nanoemulsion that was
transferred to the plasma HDL fraction after 1 hour incubation.
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shortening the blood sampling period. In many studies,
LDE kinetics was accelerated or slowed as previously
reported for the native lipoprotein [31-33]. Nonetheless, as
a limitation of those studies, the differences in protein rec-
ognition by the receptors and the compositional differences
between LDE and the native lipoprotein are to be taken
into account in the interpretation of the LDE-generated
data for extrapolation to LDL metabolism.
It is worthwhile to point out that despite the beneficial
effect on lipoprotein metabolism, as documented in this
study, patients under intensive insulin therapy have
reportedly higher cardiovascular mortality risk [34,35].
This may be ascribed to the short follow-up periods of
the insulin-treated patients, since atherosclerosis is a
long-run process. In fact, in studies with 17 and 20 year
follow-up, intensive insulin therapy achieved reduction of
events in both T1DM and type 2 diabetes mellitus; patients
were younger and had no manifestations of cardiovascular
disease when they begun the treatment [36,37].
In conclusion, although intensive insulin treatment
was not sufficient to normalize glycemia, no abnormal-
ities were found in the aspects of lipid metabolism
examined here; the LDE clearance was even increased.
Presumably, this dichotomy could have resulted from
different thresholds of insulin levels to optimize glucose,
on one hand, and plasma lipid metabolism, on the other.
Insulin bioavailability after subcutaneous administration
was also conceivably key for this outcome. The fact that
under insulin treatment optimal lipid parameters can be
attained independently of the glycemic control could be
fundamental because of the importance of dyslipidemias
in the development of diabetic macrovascular disease.
Methods
Study subjects
Fifteen male young patients with T1DM and 16 non-
diabetic healthy male subjects studied at the Outpatient
Diabetes Clinics of the Medical School Hospital of the
University of São Paulo (São Paulo, Brazil).
None of subjects had history of coronary artery disease,
dislipidemia, thyroid, gastrointestinal, inflammatory, kidney
or liver disease or history of excessive alcohol drinking.
T1DM patients were free from apparent micro and macro-
vascular diabetic complications. None of the participants
were using lipid lowering drugs. Table 5 shows the insulin
treatment scheme of the patients. As indicated in Table 1,
their glycated hemoglobin was greatly elevated.
All participants gave written informed consent. Studies
were approved by the Ethics Committee of the Medical
School Hospital of University of São Paulo.
Laboratory analysis
After an overnight fast, blood samples were taken and
total cholesterol, HDL cholesterol, and triglyceride
levels were measured using enzymatic colorimetric
methods. LDL cholesterol was calculated by direct
method (kinetic automatized). Plasma apoA-I and apoB
were assayed by turbidimetry (Roche/ Hitachi – Roche
Diagnostics, Mannheim, Germany).
A1C was measured by HPLC (National Glyco Hemoglobin
Standardization Program - NGSP-EUA, considering normal
range 4.1 a 6%). Plasma glucose concentration was
measured by a hexokinase method. Insulin sensitivity
was assessed by estimated glucose disposal rate [38],
calculated according to the formula: estimated glucose
disposal rate (EGDR) = 24.31 - 12.22*(WHR) - 3.29*
(hypertension) - 0.57*(A1C). The equation was derived
from hyperinsulinemic-euglycemic clamps performed
in 24 participants with type 1 diabetes in the Pittsburgh
Epidemiology of Diabetes Complications (EDC) Study
[38]. Original EGDR formula utilizes A. To convert
A1C in A1, the equation HbA1= 1.18 x A1C + 1.67 was
used [39].
LDE preparation
LDE was prepared from a lipid mixture composed of
40 mg cholesteryloleate, 20 mg egg phosphaditylcholine,
1 mg triolein, and 0.5 mg cholesterol. 14C-cholesteryl
oleate and 3H-cholesterol purchased from Amersham
International (Amersham, UK) were added to the mixture.
The lipid mixture was then submitted to an ultrasonic
irradiation in aqueous media, dried through nitrogen
flux, and purified by a procedure of a two-step ultra-
centrifugation procedure, as described previously [5].
LDE was dialyzed againsta saline solution and sterilized by
passage through 0.22-μm filter.
Table 5 Physical characteristics and current medications of
the Type 1 Diabetes Mellitus (T1DM) and control groups
T1DM group
(n=15)
Control group
(n=16)
P value
Age (years) 26.4 ± 7.0 28.4 ± 6.0 0.40
Age of diabetes diagnosis (years) 12.2 ± 7.2 - -
Duration of diabetes (years) 15.7 ± 7.9 - -
Body mass index (Kg/m2) 23.2 ± 2.3 25.7 ± 3.6 0.04
Waist circumference (cm) 84.3 ± 8.3 90.5 ± 9.4 0.09
Waist-to-hip ratio 0.83 ± 0.04 0.82 ± 0.05 0.80
Current smoking (%) 0 25 0.09
Arterial hypertension (%) 2 0 0.23
Insulin therapy schemes
Insulin dose (U · day– 1) 48.7 ± 13.8 - -
Insulin dose (U · kg– 1 · day– 1) 0.69 ± 0.15 - -
Insulin injections/day 3.53 ± 0.748 - -
Insulin correction bolus (%) 60 - -
Carbohydrate counting (%) 40 - -
Data are means ± SD.
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The entire nanoemulsion preparation procedure was
performed in a laminar flux. All glassware used in this
study was made pyrogen-free by exposure to dried steam at
180°C for 2 hours and sterilized by wet steam at 120°C for
30 min. All plastic materials were sterilized by ultraviolet
light exposition. The risk due to the nanoemulsion injection
is considered minimal and related to the consequences
inherent to venous puncture. The risk of infection is also
minimum, since preparations were tested for sterility and
absence of pyrogen. Furthermore, the injected nanoemul-
sion volume was extremely small, which reduces the chance
of pyrogenic reaction.
LDE plasma kinetics
The test began at approximately 8:00 AM with all partici-
pants fasting for a 12 h period. One hundred microliters
of LDE containing 37 kBq 14C-labeled cholesteryl ester
and a total of 1 mg cholesteryl ester was intravenously
injected in a bolus. Plasma samples were collected during
24 h, in intervals of 5 min and 1, 2, 4, 6, 8, and 24 h after
injection. During the first 8 h of the sample collection, all
the participants were resting in the laboratory test room
and remained seated. They were then allowed to return
home and come back to the laboratory the next day to
collect the last (24 h) blood sample. They were oriented to
rest at home. After the first blood collection, the subjects
were oriented to eat low-fat meals, as vegetables, fruits,
and fruit juices after the first blood collection.
Radioactivity in aliquots of 1.0 ml of plasma was quanti-
fied in a scintillation solution (Packard Bioscience,
Groningen, Netherlands) using a liquid scintillation
analyzer (Packard 1600 TR Model liquid scintillation
analyser, Palo Alto, CA).
Estimation of FCR of the radioisotopes
FCR of the LDE 14C-cholesteryl ester, as calculated as
described previously [34] by compartimental analysis
using a computational software (ANACOMP by C.H.
Mesquita, São Paulo, Brazil) [40,41].
Esterification of the emulsion 3H-cholesterol
Using 1.5 ml blood plasma in each point of timed colleted
blood during 24 h, lipids were extracted with chloroform-
methanol–water (2:1:1, v/v/v) overnight at 4°C. The organic
phase was transferred to a test tube and dried under
nitrogen flux. Lipids were resuspended in 5 ml of the
Folch’s solution (chlorofom-methanol, 2:1, v/v) and
transferred for test tubes. Next, the tubes were dried
under nitrogen flux, ressuspended with 300 μl of
Folch’s solution and submitted to separation by thin
layer chromatography (TLC) (silica-gel 60H, 0.5 mm
thickness), with a solvent system containing n-hexane:
Ethylic ether: acetic acid (70:30:1, v/v/v). The bands that
corresponded to cholesteryl ester and to free cholesterol,
after being developed by metallic iodine vapors, were
separated and transferred to counting vials containing
7.0 ml of scintillation solution.
An esterification ratio was calculated to determine the
proportion of unesterified to esterified cholesterol at each
experimental point (5 min and 1,2, 4, 6, 8 and 24 h) of the
radioactivity decay curve by dividing the 3H radioactivity
measured after lipid extraction at the unesterified chol-
esterol TLC band by that of the esterified cholesterol
band measured.
Lipid transfer from LDE to HDL
Two sets of LDE preparations, one labeled with 3H-choles-
teryl oleate and 14C-phosphatidylcholine and the other with
3H-triolein and 14C-cholesterol, were separately incubated
with whole plasma in a shaking bath for 60 min at 37°C
and after chemical precipitation of apoB containing
lipoproteins and LDE, the supernatant containing HDL
was counted for radioactivity, according to the method
described previously [10]. The transferred lipids from LDE
to HDL was expressed as percent (%) of the radioactivity
in the incubate measured in the supernatant.
Radiological protection
The radioactive dose used in the intravenously injected
labeledlipid experiments with the patients was in
strict accordance with the International Commission
on Radiological Protection (ICRP), as described in a
previous study [42]. The equivalent dose induced by
the injected radioactivity dose was 0.03 mSv, well
below the permitted 50.0 mSv maximum dose.
Statistical analyses
Data are presented as mean ± SD. The Kolmogorov-
Smirnov test was applied to verify the data distribution.
The Student t-test was used for normally distributed data,
and the Mann–Whitney test for those with non-Gaussian
distribution. To determinate relationship between glycemia,
A1C, insulin sensitivity and insulin therapy with kinetic
and HDL assays Pearson's correlation coefficients and
Spearman's correlation coefficients were calculated accord-
ing data distribution. SSPS version 13 software was used
for the analysis.
For all comparisons and correlations, p<0.05 were
considered statistically significant.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ACRF selected the patients, performed the experiments and data analysis,
and wrote the manuscript. GSFF performed the experiments and data
analysis. FRF contributed to discussion and wrote the manuscript. BLW
designed the clinical protocol, and contributed to discussion. RCM conceived
of the study, analyzed the results, and wrote the manuscript. All authors read
and approved the final manuscript.
Feitosa et al. Lipids in Health and Disease 2013, 12:15 Page 6 of 8
http://www.lipidworld.com/content/12/1/15
Acknowledgements
This study was supported by Fundação do Amparo à Pesquisa do Estado de
São Paulo (FAPESP), São Paulo, Brazil. Dr. Maranhão has a Research Award
from Conselho Nacional de Desenvolvimento Científico e Tecnológico
(CNPq) Brasília, Brazil.
Author details
1Heart Institute (InCor) of the Medical School Hospital, University of Sao
Paulo, São Paulo, Brazil. 2Endocrinology Service of the Medical School
Hospital, University of Sao Paulo, São Paulo, Brazil. 3Faculty of Pharmaceutic
Sciences, University of Sao Paulo, São Paulo, Brazil.
Received: 11 April 2012 Accepted: 31 January 2013
Published: 11 February 2013
References
1. Guy J, Ogden L, Wadwa RP, Hamman RF, Mayer-Davis EJ, Liese AD, Jr
D’Agostino R, Marcovina S, Dabelea D: Lipid and lipoprotein profiles in
youth with and without type 1 diabetes: the SEARCH for Diabetes in
Youth case–control study. Diabetes Care 2009, 32:416–420.
2. Erbey JR, Robbins D, Forrest KY, Orchard TJ: Low-density lipoprotein
particle size and coronary artery disease in a childhood-onset type 1
diabetes population. Metabolism 1999, 48:531–534.
3. Perez A, Caixas A, Carreras G, Mauricio D, Pou JM, Serrat J, Gómez-Gerique J, de
Leiva A: Lipoprotein compositional abnormalities in type I diabetes: effect
of improved glycaemic control. Diabetes Res Clin Pract 1997, 36:83–90.
4. Bagdade JD, Ritter MC, Subbaiah PV: Accelerated cholesteryl ester transfer
in patients with insulin-dependent diabetes mellitus. Eur J Clin Invest
1991, 21:161–167.
5. Maranhao RC, Cesar TB, Pedroso-Mariani SR, Hirata MH, Mesquita CH:
Metabolic behavior in rats of a non protein microemulsion resembling
low-density lipoprotein. Lipids 1993, 28:691–696.
6. Maranhao RC, Garicochea B, Silva EL, Dorlhiac-Llacer P, Cadena SM, Coelho
IJ, Meneghetti JC, Pileggi FJ, Chamone DA: Plasma kinetics and
biodistribution of a lipid emulsion resembling low-density lipoprotein in
patients with acute leukemia. Cancer Res 1994, 54:4660–4666.
7. Maranhao RC, Roland IA, Toffoletto O, Ramires JA, Gonçalves RP, Mesquita
CH, Pileggi F: Plasma kinetic behavior in hyperlipidemic subjects of a
lipidic microemulsion that binds to low density lipoprotein receptors.
Lipids 1997, 32:627–633.
8. Hirata RD, Hirata MH, Mesquita CH, Cesar TB, Maranhao RC: Effects of
apolipoprotein B-100 on the metabolism of a lipid microemulsion model
in rats. Biochim Biophys Acta 1999, 1437:53–62.
9. Santos RD, Chacra AP, Morikawa A, Vinagre CC, Maranhao RC: Plasma
kinetics of free and esterified cholesterol in familial
hypercholesterolemia: effects of simvastatin. Lipids 2005, 40:737–743.
10. Lo Prete AC, Dina CH, Azevedo CH, Puk CG, Lopes NH, Hueb WA, Maranhão
RC: In vitro simultaneous transfer of lipids to HDL in coronary artery
disease and in statin treatment. Lipids 2009, 44:917–924.
11. Jonas A: Lecithin cholesterol acyltransferase. Biochim Biophys Acta 2000,
1529:245–256.
12. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ,
Raskin P, Zinman B, Diabetes Control and Complications Trial/Epidemiology
of Diabetes Interventions and Complications (DCCT/EDIC) Study Research
Group: Intensive diabetes treatment and cardiovascular disease in
patients with type 1 diabetes. N Engl J Med 2005, 353:2643–2653.
13. Bagdade JD, Dunn FL: Effects of insulin treatment on lipoprotein
composition and function in patients with IDDM. Diabetes 1992, 41:107–110.
14. Bagdade JD, Dunn FL, Eckel RH, Ritter MC: Intraperitoneal insulin therapy
corrects abnormalities in cholesteryl ester transfer and lipoprotein lipase
activities in insulin-dependent diabetes mellitus. ArteriosclerThromb 1994,
14:1933–1939.
15. Rosenstock J, Vega GL, Raskin P: Effect of intensive diabetes treatment on
low-density lipoprotein apolipoprotein B kinetics in type I diabetes.
Diabetes 1988, 37:393–397.
16. Vinagre CG, Ficker ES, Finazzo C, Alves MJ, de Angelis K, Irigoyen MC,
Negrão CE, Maranhão RC: Enhanced removal from the plasma of LDL-like
nanoemulsion cholesteryl ester in trained men compared with sedentary
healthy men. J Appl Physiol 2007, 103:1166–1171.
17. Steinberg D, Lewis A, Conner Memorial Lecture: Oxidative modification of
LDL and atherogenesis. Circulation 1997, 95:1062–1071.
18. Chappell DA, Medh JD: Receptor-mediated mechanisms of lipoprotein
remnant catabolism. Prog Lipid Res 1998, 37:393–422.
19. Duvillard L, Florentin E, Lizard G, Petit JM, Galland F, Monier S, Gambert P,
Vergès B: Cell surface expression of LDL receptor is decreased in type 2
diabetic patients and is normalized by insulin therapy. Diabetes Care
2003, 26:1540–1544.
20. Kahn BB, Lilly lecture 1995: Glucose transport: pivotal step in insulin
action. Diabetes 1996, 45:1644–1654.
21. Edgerton DS, Lautz M, Scott M, Everett CA, Stettler KM, Neal DW, Chu CA,
Cherrington AD: Insulin’s direct effects on the liver dominate the control
of hepatic glucose production. J Clin Invest 2006, 116:521–527.
22. Farese RV Jr, Yost TJ, Eckel RH: Tissue-specific regulation of lipoprotein
lipase activity by insulin/glucose in normal-weight humans. Metabolism
1991, 40:214–216.
23. Stralfors P, Bjorgell P, Belfrage P: Hormonal regulation of hormone-
sensitive lipase in intact adipocytes: identification of phosphorylated
sites and effects on the phosphorylation by lipolytic hormones and
insulin. Proc Natl Acad Sci USA 1984, 81:3317–3321.
24. Eaton RP, Allen RC, Schade DS, Standefer JC: “Normal” insulin secretion: the
goal of artificial insulin delivery systems? Diabetes Care 1980, 3:270–273.
25. Duvillard L, Pont F, Florentin E, Gambert P, Vergès B: Significant
improvement of apolipoprotein B-containing lipoprotein metabolism by
insulin treatment in patients with non-insulin-dependent diabetes
mellitus. Diabetologia 2000, 43:27–35.
26. Santos RD, Hueb W, Oliveira AA, Ramires JA, Maranhao RC: Plasma kinetics
of a cholesterol-rich emulsion in subjects with or without coronary
artery disease. J Lipid Res 2003, 44:464–469.
27. Chang CK, Tso TK, Snook JT, Huang YS, Lozano RA, Zipf WB: Cholesteryl
ester transfer and cholesterol esterification in type 1 diabetes:
relationships with plasma glucose. Acta Diabetol 2001, 38:37–42.
28. Maranhao RC, Freitas FR, Strunz CM, Santos RD, Mansur AJ, Mansur AP: Lipid
transfers to HDL are predictors of precocious clinical coronary heart
disease. Clin Chim Acta 2012, 413:502–505.
29. Rocha MP, Maranhao RC, Seydell TM, Barcellos CR, Baracat EC, Hayashida SA,
Bydlowski SP, Marcondes JA: Metabolism of triglyceride-rich lipoproteins
and lipid transfer to high-density lipoprotein in young obese and
normal-weight patients with polycystic ovary syndrome. Fertil Steril 2010,
93(6):1948–1956.
30. Dullaart RP, Groener JE, Dikkeschei LD, Erkelens DW, Doorenbos H:
Increased cholesterylester transfer activity in complicated type 1
(insulin-dependent) diabetes mellitus–its relationship with serum
lipids. Diabetologia 1989, 32:14–19.
31. Goldberg RB, Mellies MJ, Sacks FM, Goldberg RB, Mellies MJ, Sacks FM, Moyé
LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E:
Cardiovascular events and their reduction with pravastatin in diabetic
and glucose-intolerant myocardial infarction survivors with average
cholesterol levels: subgroup analyses in the cholesterol and recurrent
events (CARE) trial. The care investigators. Circulation 1998, 98:2513–2519.
32. Kissebah AH, Alfarsi S, Evans DJ, Adams PW: Plasma low density
lipoprotein transport kinetics in noninsulin-dependent diabetes mellitus.
J Clin Invest 1983, 71:655–667.
33. Kissebah AH: Low density lipoprotein metabolism in non-insulin-
dependent diabetes mellitus. Diabetes Metab Rev 1987, 3:619–651.
34. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B,
Billot L, et al: Intensive blood glucose control and vascular outcomes in
patients with type 2 diabetes. N Engl J Med 2008, 12:2560–2572.
35. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve
FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek
ME, Henderson WG, Huang GD, VADT Investigators: Glucose control and
vascular complications in veterans with type 2 diabetes. N Engl J Med 2009,
8:360. 129–39.
36. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ,
Raskin P, Zinman B, Diabetes Control and Complications Trial/Epidemiology
of Diabetes Interventions and Complications (DCCT/EDIC) Study Research
Group: Intensive diabetes treatment and cardiovascular disease in
patients with type 1 diabetes. N Engl J Med 2005, 22:353. 2643–53.
37. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR: Long-term follow-
up after tight control of blood pressure in type 2 diabetes. N Engl J Med
2008, 9:359. 1565–76.
38. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ: Can clinical factors
estimate insulin resistance in type 1 diabetes? Diabetes 2000, 49:626–632.
Feitosa et al. Lipids in Health and Disease 2013, 12:15 Page 7 of 8
http://www.lipidworld.com/content/12/1/15
39. James TM, Davis JE, McDonald JM, Santiago JV, Ladenson JH: Comparison
of hemoglobin A1c and hemoglobin A1 in diabetic patients. Clin Biochem
1981, 14:25–27.
40. Couto RD, Dallan LA, Lisboa LA, Mesquita CH, Vinagre CG, Maranhão RC:
Deposition of free cholesterol in the blood vessels of patients with
coronary arterydisease: a possible novel mechanism for atherogenesis.
Lipids 2007, 42:411–418.
41. da Silva JL, Vinagre CG, Morikawa AT, Alves MJ, Mesquita CH, Maranhão RC:
Resistance training changes LDL metabolism in normolipidemic subjects:
a study with a nanoemulsion mimetic of LDL. Atherosclerosis 2011,
219(2):532–537.
42. Sowby FS: Radiation protection. In Limits for Intakes of Radionuclides by
Workers. Oxford: ICRP publication 30. Part I. Pergamon; 1984.
doi:10.1186/1476-511X-12-15
Cite this article as: Feitosa et al.: Lipoprotein metabolism in patients
with type 1 diabetes under intensive insulin treatment. Lipids in Health
and Disease 2013 12:15.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Feitosa et al. Lipids in Health and Disease 2013, 12:15 Page 8 of 8
http://www.lipidworld.com/content/12/1/15
